$CTS

CTS Corp. (CTS) announced its sensing solutions will now be sold through authorized distribution partners, targeting non-automotive, high-growth markets. Shares have declined 11.77% over 30 days but are up 29.01% year-to-date. Analysts suggest the stock may be 13% undervalued at $56.57, with a fair value estimate of $65, citing future earnings growth and margin expansion. However, the company faces challenges from weaker transportation demand and competitive pressures in Europe.

Argus on Aug 12, 2026 lowered its target price for CTS Corp (CTS) to $72.00. The note describes CTS Corp as an electronics manufacturer of sensors, electronic components, and actuators. Other listed items include target or rating changes for APH, IPGP, ESE, AGYS, and LFUS.

Vietnam’s VN-Index slipped slightly around 1,770 as investors turned cautious amid profit-taking and mixed sector moves. Liquidity eased to 640.8M shares worth VND16.01T on Ho Chi Minh City. GAS led declines, while LPB, MBB, OCB and brokerages like VIX, TCV, CTS gained. State-owned stocks retreated after Monday’s rally.

Gabelli-related entities filed a Schedule 13D/A stating they collectively hold 5.75% of CTS Corp (CTS), according to the filing. The document describes the reporting persons’ corporate relationships and investment-advisory roles, and notes CTS is a public company with stock quoted on OTCQX for one parent entity.

CTS (CTS) reported Q2 results with management citing growth in medical, industrial, and aerospace/defense, plus operational improvements and a more profitable sales mix. It noted modest transportation declines and one-time items that boosted EPS. Analysts asked about CEO strategy, R&D recurrence, medical margins, pricing and cost inflation, and transportation outlook. CTS shares were about $65.25 after earnings.

Simply Wall St reports CTS Corporation’s Q2 2026 results: sales of $144.78M and net income of $19.16M. The company raised full-year 2026 sales guidance to $565M to $585M and completed a $21.73M share repurchase totaling 468,772 shares since Nov 2025. The article discusses how these updates may affect CTS’s investment case.

CTS Corporation reported Q2 2026 gross margin of 41.5% and said diversified end markets now make up 59% of revenue. Medical sales grew 45% YoY, industrial rose 16%, while transportation fell 2%. Full-year 2026 sales guidance was raised to $565-$585 million. Management expects aerospace strength in H2 and cautions on tariffs and precious metal inflation.

Morgan Stanley research cited by the article says the median S&P 500 EPS surprise was 6% in Q1 2026, above the long-run ~5.5% average. FactSet research cited says firms with positive EPS surprises tend to keep outperforming after results. The article lists 28 companies that beat Wall Street EPS expectations, including Ford (EPS $0.66 vs $0.31), Bloom Energy (EPS $0.78 vs $0.37; revenue >$1B, +164% YoY), and Incyte (EPS $3.09 vs $0.94).

CTS Corp. (CTS) shares rose about 4% on Tuesday after the company reported higher Q2 profit and raised its FY2026 outlook. Q2 net earnings increased to $19.16M from $18.53M, EPS to $0.66 from $0.62, and net sales to $144.78M from $135.31M. FY26 guidance lifted to $565-$585M sales and $2.55-$2.70 adjusted EPS.

CTS Corporation (NYSE: CTS) shares rose about 5.8% after the company reported Q2 results that beat expectations and raised full-year guidance. CTS said sales were $144.8 million (+7% YoY) and adjusted EPS was $0.74. It now expects 2026 revenue around $575 million (midpoint) and adjusted EPS of $2.63 (midpoint).